Objective: Abuse of inhalants containing the volatile solvent toluene is a significant public health issue, especially for adolescent and Indigenous communities. Adolescent inhalant abuse can lead to chronic health issues and may initiate a trajectory towards further drug use. Identification of at-risk individuals is difficult and diagnostic tools are limited primarily to measurement of serum toluene. Our objective was to identify the effects of adolescent inhalant abuse on subsequent drug use and growth parameters, and to test the predictive power of growth parameters as a diagnostic measure for inhalant abuse.
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These products are cheap, legal and readily accessible, adding to their attractiveness as substances of abuse. A recent stratified and randomised selection survey of more than 26,000 people aged 12 years and older from across Australia, by the Australian government, found a 23% increase in inhalant abuse, 2 highlighting its growing popularity.
In Australia inhalant abuse, especially petrol sniffing, remains a significant issue for Indigenous communities with rates up to 60% in some remote communities. 3 However in recent years, inhalant abuse has also become prevalent among young adolescents, irrespective of ethnicity, as determined by both the household drug survey and a specialised survey of 25,000 Australian secondary school students aged 12-17. 2, 4 This is concerning as adolescence encompasses a critical period of maturation, which can be disrupted by exposure to harmful substances. 5 Inhalant abuse during this period is associated with long-term adverse health outcomes affecting both central and peripheral processes, including cognitive dysfunction, renal tubular acidosis, hepatic dysfunction and bone marrow suppression. 6 Despite its prevalence and associated harms, inhalant abuse remains a poorly recognised problem. 6 There are reported warning signs to identify inhalant abuse, but these refer predominantly to acute effects, which are highly transient. 6 The Diagnostic and Statistical Manual of Mental Disorders IV contains criteria for inhalant abuse, but for a diagnosis to be made, an individual needs to be in the care of a psychological or health professional. Therefore, the first level of recognition of inhalant abuse often relies on a high index of suspicion from parents/guardians, teachers or health care workers before referral to an appropriate health professional can occur, which makes diagnosis problematic. Additionally, inhalant abuse rates are typically highest in populations of vulnerable youth, which have reduced contact with the primary health care system. 7 Toluene is the primary volatile solvent in abused products, and therefore serum toluene can be used as an acute diagnostic test. However, toluene is rapidly metabolised, which limits its diagnostic capabilities. 8 As creatine kinase is elevated in response to petrol sniffing it has also been suggested as a potential diagnostic tool, though its relevance to inhalants other than petrol remains unknown. 9 For most users, the pattern of inhalant abuse is chronic but intermittent, 10 which highlights the need for diagnostic markers that are more responsive to sustained use. Chronic inhalant abuse is associated with long-term health and psychological harm including increased use of other drugs, 11 cognitive decline and brain injury 12 and adverse psychological consequences including suicide. 13 Inhalant abuse, especially during adolescence,
Adolescent inhalant abuse leads to other drug use and impaired growth; implications for diagnosis
can also affect peripheral body systems, including those that regulate metabolism and growth. [14] [15] [16] Thus a more robust diagnostic method, which can be applied to chronic inhalant abuse, may increase detection and provide an opportunity for intervention strategies, to limit adverse neuropsychological, metabolic and growth outcomes.
Profiles of subsequent drug use and growth impairment arising from adolescent inhalant abuse are compelling targets for further research, given that their incidence may contribute to psychological harm and chronic health effects. This study aimed to characterise patterns of other drug use and effects on growth in a cohort of adolescent inhalant abusers from a population of Indigenous males. It also aimed to understand whether growth parameters could represent a diagnostic tool to identify chronic inhalant abuse in adolescents, including whether the effects were severe enough to meet clinical 'failure to thrive' (FTT) criteria.
Method
This study retrospectively analysed an historical dataset, collected with the aim of investigating the social and neurological outcomes of adolescent inhalant abuse in Indigenous populations. Data collection methods have been previously described in detail, 9, 12, 17 but are summarised here and discussed in the following paragraphs. Data was collected from two remote Indigenous communities, where petrol sniffing had been prevalent for many years. All subjects were interviewed about petrol sniffing and other drug use behaviour using a consensus methodology with survey instruments developed specifically for this project, and underwent a health check that included neurological and cognitive examinations, collection of a blood sample, and height and weight measurements.
Participants
Ethical approval for data collection was obtained from the institutional ethics committee, an independent Indigenous ethics committee, and town councils from the communities in the study. 
Drug use survey
Classification into petrol sniffing or control groups was based upon a consensual methodology, requiring corroboration from the individual, community health workers, research assistants and local health records. Each participant's self-reported history was compared with local community clinic health records, an assessment by a community health worker, and an assessment of petrol sniffing behaviour by research assistants recruited from the same language group. If data was consistent across all these sources, it was deemed to be an accurate reflection of petrol sniffing history and the participant was included in the study 12 and furthermore, consistency between the consensual assessment and self-assessment was high. 18 All participants in the petrol sniffing group met the criteria for inhalant abuse from the Diagnostic and Statistical Manual of Mental Disorders IV. Drug use data were collected through an interview survey administered by the same researcher in conjunction with an Indigenous Research Assistant recruited from the same language group. This included age of onset/age petrol sniffing commenced (years), duration (years), and severity (scale of 1-5: 1/2=light/intermittent, 3=moderate, 4/5=heavy). The severity score was self-rated based upon petrol sniffing behaviour in the previous 12 months and was validated through a significant positive correlation with the volume of petrol that participants reported having sniffed each week.
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Participants were also surveyed regarding other drug use including alcohol, cigarette smoking, kava and marijuana. 
Haematological measures

Parameters of growth
Height (cm) and weight (kg) were measured by the research team at the time of the interview and body mass index (BMI) calculated (weight (kg)/height squared (m 2 )). Weight was measured on an electronic scale and height was measured using a tape. These measures were undertaken by a single trained individual, to prevent inter-rater variability. Growth percentiles were calculated using US Centre for Disease Control (CDC) 2000 growth charts (males aged 0-20 years 19 ) and the CDC National Health and Nutrition Examination Survey (males > 20 years 20 ). The criteria for meeting a FTT diagnosis were weight below the 3 rd percentile or 20% below ideal weight for height, when compared to standard growth charts, 21 only one criterion had to be met.
Pooled groups
In initial studies using these participants; individuals with a history of petrol sniffing were separated based on the presence or absence of lead encephalopathy. For this study, growth metrics were not different between these individuals, nor individuals between the two communities, and therefore individuals were not maintained in separate groups for this study. To investigate the need to control for the effects of other drug use on growth, groups were stratified into the following; controls who use no other drugs (n=15), controls who use one or two other drug type use (n=13), controls who use three or more other drugs (n=4) petrol sniffing with no other drug use (n=9), petrol sniffing who use one or two other drugs (n=66), petrol sniffing who use three or more other drugs (n=11). These stratifications did not result in any significant intra-group differences in height or weight (p>0.05). Thus individuals were pooled to form two groups; petrol sniffing and non-petrol sniffing control.
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Data analysis
Statistical analysis was conducted using IBM SPSS Statistics 22 and power calculations were conducted using G*Power 3.1.9.2. Data for each variable was assessed for normality, and normalised as necessary using square root transformation. Group differences were investigated using independent sample t-tests. The linear relationship between continuous variables was investigated using linear regression and 2-tailed Pearson Correlation coefficients. Chi-square tests were used to investigate the relationship between categorical variables. Significance was set at p≤0.05; trends reported at p>0.05 but ≤0.10.
Results are reported as mean±SEM.
Results
Petrol sniffing
The age of commencement for petrol sniffing was 12.9±0.4 years. The average duration was 8.6±0.8 years and severity score 4.1±0.4. There were significant linear correlations between all three metrics of petrol sniffing behaviour (Supplementary Table 2) , with the severity of petrol sniffing being predicted by both duration and age of commencement (p=0.012, linear regression). There was also a significant correlation between the severity score and blood lead levels (p=0.014), confirming the validity of the severity score.
Other drug use
Petrol sniffing was predominantly the first drug used, with 48.1% of all petrol sniffing individuals reporting that as their first substance; cigarette smoking was the next most common first substance (6.5%). In comparison, cigarette smoking was the most common first substance in the control group (17.6%); alcohol consumption the next most common (11.8%). Petrol sniffing was associated with an increased proportion of all other drug use (trend for alcohol, p=0.053) and with earlier other drug use, which was significant for the average age of commencement of cigarette and kava use, with trends for earlier alcohol (p=0.055) and marijuana (p=0.084) use (Table 1) . Furthermore, the age that sniffing commenced was positively linearly correlated with age of other drug use commencement for cigarette smoking (p=0.022), kava (p=0.048) and marijuana (p=0.040), but not alcohol. The severity of other drug use was not significantly different between petrol sniffing and non-sniffing groups (Table 1) . 
Haematological data
Results for haematological variables are shown in Supplementary Table 1 . There was a significant difference in serum toluene levels (p<0.000) between petrol sniffing (0.06±0.02 µg/mL) and non-petrol sniffing groups (0.00±0.00 µg/mL). However, 73.5% of petrol sniffing individuals had 0.00 µg/mL serum toluene.
There was a significant difference in creatine kinase levels (p=0.002) between petrol sniffing (420.2±39.3 U/L) and non-petrol sniffing groups (212.7±22.4 U/L). There was a significant group difference in exceeding the creatine kinase reference range (p=0.035, chi square). Neither serum toluene nor creatine kinase levels were correlated with any of the three metrics of petrol sniffing behaviour (p>0.05).
Growth data
There was a significant difference in height ( Figure 1A ) and weight ( Figure 1B ) between petrol sniffing and non-petrol sniffing groups, with petrol sniffing individuals on average 5 cm shorter (p<0.000, with power of 0.95) and 7 kg lighter (p=0.001, with power of 0.86). The regression co-efficient for weight as predicted by height was 0.70 (p<0.000) in the petrol sniffing group and 0.84 (p=0.003) in the non-petrol sniffing group. There was also a significant difference in height-for-age Figure 2 ). Increased duration of petrol sniffing was linearly associated with reduced height percentile (p=0.024, linear regression, Figure 3 ), but not weight percentile. Age of commencement and severity of petrol sniffing were not correlated with either height or weight percentiles. When stratified into sub-groups by other drug use, there were no significant intra-group differences in height or weight. Furthermore, there was no significant difference between groups for BMI ( Figure  1C ) and BMI percentile.
Failure to thrive
Of the petrol sniffing group, 49% were less than 3rd percentile for weight and thus met FTT criteria compared to 25% in the nonsniffing group (p=0.022, chi square). Of the 48 individuals who met FTT criteria, 83% were petrol sniffing individuals.
Diagnosing petrol sniffing
The existing diagnostic model of serum toluene had a sensitivity of 27% and a specificity of 100% with an overall accuracy of 47%, reflecting the high rate of false negatives with no false positives. Creatine kinase had a sensitivity of 35% and a specificity of 84% with overall accuracy of 49%. Using FTT as a diagnostic model resulted in a sensitivity of 49% and a specificity of 75% with overall accuracy of 56%, reflecting a lower rate of false negatives.
Discussion
We explored the effects of chronic petrol sniffing during adolescence on subsequent drug use and growth in a cohort of Indigenous males. We expanded initial observations from this dataset 18 to show that petrol sniffing was associated with increased and earlier onset of subsequent drug use, and the commencement age of petrol sniffing also correlated positively with that of other drug use. Petrol sniffing also impaired both height and weight, and weight impairments were so severe that half the petrol sniffing individuals met FTT diagnosis. In this cohort, growth impairment out-performed serum toluene and creatine kinase as diagnostic models of chronic inhalant abuse, and FTT had the highest sensitivity and overall accuracy for chronic petrol sniffing, which represents a novel and practical diagnostic tool for this behaviour.
In our cohort, petrol sniffing commenced in early adolescence and was predominantly the first substance misused; a consistent finding with other demographic studies in Australia and overseas. 2, 22 Additionally, commencement age was positively correlated with severity and duration of petrol sniffing. This relationship is important as duration of petrol sniffing significantly increases the magnitude of neurological and cognitive deficits. 12 The findings of increased and earlier drug use after petrol sniffing are consistent with other studies suggesting that inhalant use appears to establish a trajectory towards other drug use (see for review Dinwiddie 1994) . 11 This is of significant concern as increased drug use in adolescence is associated with neurocognitive pathology and impairment 5 and is a risk factor for ongoing psychological harm. 23 A history of drug use also increases the risk of psychotic outcomes including suicide. 24 Thus adolescent inhalant abuse may have a direct contribution to lifelong psychological impacts, and also contribute indirectly by increasing subsequent drug use. These findings highlight the need for early diagnosis and intervention of inhalant abuse, ideally before individuals' progress to other drugs of abuse. Petrol sniffing during adolescence significantly impaired weight. In humans, adolescent inhalant abuse is associated with weight loss and emaciation. 15 These findings are recapitulated in rodent studies and associated with reduced food intake in the absence of anhedonia, decreased weight gain and reduced fat deposition. 14 In humans there is evidence that incidental inhalation of petrol fumes may have an acute anorectic effect, 25 suggesting that weight impairment may be driven by decreased food intake, while others suggest that toluene exposure results in a higher basal metabolic rate 26 or alters appetite regulating hormones. 14 Body weight is driven by a complex relationship between food intake, metabolic function, body composition and energy expenditure; 27 our dataset does not allow mechanistic interpretation. Nevertheless, the observed weight impairments were so severe that nearly 50% of petrol sniffing individuals met FTT criteria. FTT is not a disease, but rather a symptomatic description of poor growth attributable to many causes, including malnutrition or psychosocial factors including poverty. 28 Whilst the baseline prevalence of FTT is higher in Indigenous populations compared to non-Indigenous populations, 29 we identified differences in the FTT rates within these two communities, based upon a history of petrol sniffing in adolescence. Importantly, childhood FTT is associated with an increased risk of subsequent disease development, including obesity and cardiovascular disease. 30 Adolescent petrol sniffing also significantly impaired height, a novel finding. Height was also a significant predictor of weight in both petrol sniffing and non-petrol sniffing individuals, suggesting that the weight impairments may be partially attributable to impaired height. Adolescence encompasses an intensive period of growth (adolescent growth spurt) where over half of the peak bone mass is attained. 31 For males, the growth spurt initiates around 12 years of age and ends at about 20 years of age, 32 which coincides with the primary time of petrol sniffing behaviour in this study.
As this growth spurt can be disrupted by factors such as malnutrition 33 it is likely that inhalant abuse could disrupt this intensive growth period, including skeletal growth. Indeed chronic toluene exposure impairs both skeletal growth and bone mineral density in rats 16, 34 and bone mineral density in adolescent males with a history of chronic glue sniffing. 35 Any disruption to growth during adolescence has the potential to cause long-term effects on stature. 36 As both height and weight were reduced, there was no change in BMI between petrol sniffing and non-petrol sniffing groups. This highlights the risk of using BMI as a primary metric of growth.
Current diagnostic tools for inhalant abuse are limited, and restricted to presentation to a medical facility under acute intoxication, and the subsequent measurement of serum toluene or creatine kinase levels. In this study, 73.5% of the petrol sniffing individuals had a zero reading of serum toluene within 12 hours of petrol sniffing. Creatine kinase levels were elevated by petrol sniffing and may provide a more temporally stable measure than serum toluene. 9 However, the relevance of creatine kinase to inhalants other than petrol is unknown. Furthermore, creatine kinase levels can be increased by other environmental factors such as high ambient temperature 37 or other drug use. 38 Neither serum toluene nor creatine kinase correlated with severity or duration of petrol sniffing behaviour and were therefore not helpful metrics for diagnosing chronic inhalant abuse.
Importantly, the measures indicated above require acute presentation to a medical facility, given their requirement for blood collection. Since inhalant abuse is associated with low socioeconomic status and inhalant abusers are disproportionately represented in the mental health and protective services systems, these populations have less regular contact with the medical system. 7 In addition, petrol sniffing among Indigenous people occurs predominantly in remote communities, where access to health services is limited. Therefore we investigated whether the effects of inhalants on growth could be incorporated into a novel diagnostic tool for identifying chronic inhalant abuse. In our study, height percentile was significantly impaired by petrol sniffing and importantly, was also negatively correlated with increased duration of petrol sniffing behaviour, suggesting this metric may be sensitive to identifying the nuances of chronic abuse. Furthermore, individuals with a history of petrol sniffing met FTT criteria more frequently than non-sniffers. Thus growth metrics may be a clinically relevant tool for identifying chronic adolescent inhalant abuse having higher sensitivity and overall accuracy than any of the existing diagnostic tools. In addition, growth metrics were almost twice as sensitive as serum toluene in identifying chronic inhalant abuse. For a screening test, sensitivity is more valuable than specificity, as the focus for inhalant abuse needs to be on improving the identification of a serious but treatable condition.
The use of growth metrics as a diagnostic tool is feasible, given that body growth is routinely measured by an individual or a parent/ guardian, it does not change rapidly and measurement does not require contact with the primary health care system or specialised equipment. This may be especially valuable for disadvantaged and remote populations. It is unknown how quickly growth is impaired by inhalant abuse; therefore, this approach is more likely to be applicable to chronic use. Growth impairments arising from adolescent inhalant abuse may also provide the basis of a powerful health education message. Evidence suggests that some inhalant users are motivated by a desire to restrict their weight; 39 however, it may be less desirable to also restrict height. This health promotion message may also be relevant to the study group we investigated, adolescent Indigenous males, where size and strength are highly valued personal attributes. 40 Our data were retrospectively analysed from a historic cohort of Indigenous males from two remote communities. However, data from human inhalant abuse is difficult to obtain and, as drug use, growth and FTT are common measures of health and development, this study provides relevant observations. One limitation of this study is that birth weight data was not available; in order to assess growth trajectories prior to petrol sniffing. However, the use of a control group from the same communities in this study provides some mitigation for this potential confound. Furthermore, while low socioeconomic status and disadvantage are risk factors for FTT, and are associated with inhalant use, the control group also provides mitigation for the risk of these factors confounding our findings. In addition, our ability to extrapolate these findings to females or to urban populations is limited. There is also a potential confound of lead in this cohort, as individuals sniffed a combination of leaded and unleaded petrol, which has also been associated with impaired weight and height. 41 However, we suggest that these findings are relevant to other inhalants, as toluene is a common solvent in all inhaled products and animal studies using toluene have shown similar growth impairments as in this study. 14, 16 While further work will be needed to identify the mechanisms underlying these growth impairments, particularly the effect of inhalant-induced appetite suppression, the persistence of these effects into abstinence, and the health consequences of growth impairment during adolescence, we suggest that height impairment should be added to advisory notes as a warning sign of inhalant abuse.
This is the first study that has established a link between FTT and adolescent inhalant abuse, potentially providing a novel diagnostic technique for chronic inhalant abuse thus increasing the opportunity for intervention. Early intervention is effective in relation to petrol sniffing as cognitive impairments can resolve with sustained abstinence. 17 Furthermore, early intervention can reduce subsequent drug use, adverse psychological outcomes and other high-risk behaviours. 42 We suggest that inhalant abuse should be added to the differential diagnosis guidance for FTT in high risk populations and age groups.
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Conclusion
This study shows that petrol sniffing is typically the first substance misused and is associated with increased and earlier use of other drugs. This misuse commences during a critical period for maturational processes. Petrol sniffing significantly impaired weight and height, independent of other drug use, to the extent that many individuals met the criteria for a FTT diagnosis. In combination, these findings suggest that adolescent inhalant abuse can initiate a trajectory of substance misuse and growth impairment, and thus highlights the need for early diagnosis. Using growth parameters as a diagnostic tool for inhalant abuse may be clinically valuable as they are simple to implement and can be translated into populations where inhalant abuse is more prevalent. Given the current difficulties in identifying inhalant misuse, our study provides a novel opportunity for improving diagnostic capabilities thus leading to earlier intervention, in order to alter the trajectory of ongoing drug use and prevent chronic adverse psychological and health consequences.
